Prognostic factors in paediatric acute liver failure

M Ciocca1, M Ramonet, M Cuarterolo

  • 1Division of Gastroenterology, Children's Hospital Juan P Garrahan, Combate de los Pozos 1881 (CP 1245), Ciudad Autónoma de Buenos Aires, Argentina. mciocca@intramed.net.ar

Insights

Hepatitis A is the primary cause of pediatric acute liver failure (ALF) in Argentina. Advanced encephalopathy and prolonged prothrombin time predict poor outcomes, but King's College criteria effectively assess prognosis in children.

Area of Science:

  • Pediatric Hepatology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Acute liver failure (ALF) in children presents a significant clinical challenge with varying etiologies and outcomes.
  • Identifying reliable prognostic indicators is crucial for timely intervention and management.

Purpose of the Study:

  • To investigate the causes, outcomes, and prognostic factors in pediatric patients diagnosed with acute liver failure.
  • To evaluate the applicability of King's College criteria for predicting ALF outcomes in children.

Main Methods:

  • A retrospective chart review was conducted on 210 pediatric patients (median age 5.33 years) with ALF.
  • Patients were categorized into survival, death, or liver transplantation (LT) groups.
  • King's College criteria were assessed for their predictive value.

Main Results:

  • Hepatitis A was the leading cause of ALF (61%), followed by indeterminate causes (32%).
  • Multivariate analysis identified prothrombin time and advanced encephalopathy (III/IV) as significant predictors of mortality.
  • King's College criteria demonstrated high positive predictive values (95-96%) and negative predictive values (82%) for predicting outcomes, including the need for LT.

Conclusions:

  • Hepatitis A is the predominant etiology of pediatric ALF in Argentina.
  • Prognostic indicators such as advanced encephalopathy and prolonged prothrombin time are strongly associated with adverse outcomes or the need for liver transplantation.
  • King's College criteria are validated for predicting ALF outcomes in pediatric populations, including cases attributed to hepatitis A.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...